{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:08:51Z","timestamp":1792782531062,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"CSCO-Hengrui Cancer Research Fund","award":["Y-HR2019-0239"],"award-info":[{"award-number":["Y-HR2019-0239"]}]},{"name":"CSCO-Hengrui Cancer Research Fund","award":["Y-HR2020QN-0414"],"award-info":[{"award-number":["Y-HR2020QN-0414"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2019-I2M-5-035"],"award-info":[{"award-number":["2019-I2M-5-035"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-061"],"award-info":[{"award-number":["2021-I2M-1-061"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2022-I2M-C&T-A-003"],"award-info":[{"award-number":["2022-I2M-C&T-A-003"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-128"],"award-info":[{"award-number":["2022-PUMCH-B-128"]}]},{"name":"CSCO-MSD Cancer Research Fund","award":["Y-MSDZD2021-0213"],"award-info":[{"award-number":["Y-MSDZD2021-0213"]}]},{"DOI":"10.13039\/501100018538","name":"National Ten-thousand Talent Program","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018538","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s00262-023-03523-2","type":"journal-article","created":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T06:03:15Z","timestamp":1696312995000},"page":"3717-3726","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis"],"prefix":"10.1007","volume":"72","clinical-trial-number":[{"clinical-trial-number":"nct03892577","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jiashuo","family":"Chao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunchao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengpei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingnan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjian","family":"Piao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,3]]},"reference":[{"key":"3523_CR1","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3322\/caac.21759","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME (2023) Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin 73:198\u2013222","journal-title":"CA Cancer J Clin"},{"key":"3523_CR2","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX (2021) Biliary tract cancer. Lancet 397:428\u2013444","journal-title":"Lancet"},{"key":"3523_CR3","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1002\/cncr.32803","volume":"126","author":"AA Florio","year":"2020","unstructured":"Florio AA, Ferlay J, Znaor A, Ruggieri D, Alvarez CS, Laversanne M et al (2020) Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. Cancer 126:2666\u20132678","journal-title":"Cancer"},{"key":"3523_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273\u20131281","journal-title":"N Engl J Med"},{"key":"3523_CR5","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A et al (2021) Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol 22:690\u2013701","journal-title":"Lancet Oncol"},{"key":"3523_CR6","doi-asserted-by":"publisher","first-page":"EVIDoa200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, Ruth He A, Qin S, Chen L-T, Okusaka T, Vogel A et al (2022) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 1:EVIDoa200015","journal-title":"NEJM Evid"},{"key":"3523_CR7","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z et al (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401:1853\u20131865","journal-title":"Lancet"},{"key":"3523_CR8","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/hep.31092","volume":"72","author":"S Job","year":"2020","unstructured":"Job S, Rapoud D, Dos Santos A, Gonzalez P, Desterke C, Pascal G et al (2020) Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma. Hepatology 72:965\u2013981","journal-title":"Hepatology"},{"key":"3523_CR9","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamaoncol.2020.0930","volume":"6","author":"RD Kim","year":"2020","unstructured":"Kim RD, Chung V, Alese OB, El-Rayes BF, Li D, Al-Toubah TE et al (2020) A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol 6:888\u2013894","journal-title":"JAMA Oncol"},{"key":"3523_CR10","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/ijc.33013","volume":"147","author":"SA Piha-Paul","year":"2020","unstructured":"Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A et al (2020) Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer 147:2190\u20132198","journal-title":"Int J Cancer"},{"key":"3523_CR11","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1002\/hep.32023","volume":"74","author":"L Torrens","year":"2021","unstructured":"Torrens L, Montironi C, Puigveh\u00ed M, Mesropian A, Leslie J, Haber PK et al (2021) Immunomodulatory effects of Lenvatinib plus anti-programmed cell death protein 1 in mice and rationale for patient enrichment in hepatocellular carcinoma. Hepatology 74:2652\u20132669","journal-title":"Hepatology"},{"key":"3523_CR12","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1159\/000505695","volume":"9","author":"H Deng","year":"2020","unstructured":"Deng H, Kan A, Lyu N, Mu L, Han Y, Liu L et al (2020) Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits antitumor immunity and enhances programmed cell death-1 checkpoint blockade in hepatocellular carcinoma. Liver Cancer 9:338\u2013357","journal-title":"Liver Cancer"},{"key":"3523_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK (2018) Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol 15:325\u2013340","journal-title":"Nat Rev Clin Oncol"},{"key":"3523_CR14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1200\/JCO.2021.39.3_suppl.321","volume":"39","author":"L Villanueva","year":"2021","unstructured":"Villanueva L, Lwin Z, Chung HC, Gomez-Roca C, Longo F, Yanez E et al (2021) Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study. J Clin Oncol 39:321\u2013321","journal-title":"J Clin Oncol"},{"key":"3523_CR15","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1200\/JCO.2021.39.15_suppl.4099","volume":"39","author":"Z Jian","year":"2021","unstructured":"Jian Z, Fan J, Shi G-M, Huang X-Y, Wu D, Liang F et al (2021) Lenvatinib plus toripalimab as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-arm, phase 2 trial. J Clin Oncol 39:4099\u20134099","journal-title":"J Clin Oncol"},{"key":"3523_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4103\/picr.picr_62_21","volume":"12","author":"D Chodankar","year":"2021","unstructured":"Chodankar D (2021) Introduction to real-world evidence studies. Perspect Clin Res 12:171\u2013174","journal-title":"Perspect Clin Res"},{"key":"3523_CR17","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1159\/000522403","volume":"11","author":"S Kubo","year":"2022","unstructured":"Kubo S, Shinkawa H, Asaoka Y, Ioka T, Igaki H, Izumi N et al (2022) Liver cancer study group of japan clinical practice guidelines for intrahepatic cholangiocarcinoma. Liver Cancer 11:290\u2013314","journal-title":"Liver Cancer"},{"key":"3523_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, Kelley RK, Kl\u00fcmpen HJ, Malka D et al (2023) Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 34:127\u2013140","journal-title":"Ann Oncol"},{"key":"3523_CR19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.lungcan.2019.06.012","volume":"134","author":"M Dietel","year":"2019","unstructured":"Dietel M, Savelov N, Salanova R, Micke P, Bigras G, Hida T et al (2019) Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: the global, multicenter EXPRESS study. Lung Cancer 134:174\u2013179","journal-title":"Lung Cancer"},{"key":"3523_CR20","doi-asserted-by":"crossref","unstructured":"Chen X, Wu X, Wu H, Gu Y, Shao Y, Shao Q et al (2020) Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. J Immunother Cancer 8","DOI":"10.1136\/jitc-2020-001240"},{"key":"3523_CR21","doi-asserted-by":"publisher","first-page":"907055","DOI":"10.3389\/fonc.2022.907055","volume":"12","author":"X Ding","year":"2022","unstructured":"Ding X, Li G, Sun W, Shen Y, Teng Y, Xu Y et al (2022) Sintilimab combined with lenvatinib for advanced intrahepatic cholangiocarcinoma in second-line setting-a multi-center observational study. Front Oncol 12:907055","journal-title":"Front Oncol"},{"key":"3523_CR22","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","volume":"33","author":"M Maio","year":"2022","unstructured":"Maio M, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, Cassier PA et al (2022) Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol 33:929\u2013938","journal-title":"Ann Oncol"},{"key":"3523_CR23","doi-asserted-by":"publisher","first-page":"7452","DOI":"10.18632\/oncotarget.13918","volume":"8","author":"EA Kautto","year":"2017","unstructured":"Kautto EA, Bonneville R, Miya J, Yu L, Krook MA, Reeser JW et al (2017) Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS. Oncotarget 8:7452\u20137463","journal-title":"Oncotarget"},{"key":"3523_CR24","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1373\/clinchem.2014.223677","volume":"60","author":"SJ Salipante","year":"2014","unstructured":"Salipante SJ, Scroggins SM, Hampel HL, Turner EH, Pritchard CC (2014) Microsatellite instability detection by next generation sequencing. Clin Chem 60:1192\u20131199","journal-title":"Clin Chem"},{"key":"3523_CR25","doi-asserted-by":"publisher","first-page":"e1294","DOI":"10.1634\/theoncologist.2019-0236","volume":"24","author":"J Cao","year":"2019","unstructured":"Cao J, Chen L, Li H, Chen H, Yao J, Mu S et al (2019) An accurate and comprehensive clinical sequencing assay for cancer targeted and immunotherapies. Oncologist 24:e1294\u2013e1302","journal-title":"Oncologist"},{"key":"3523_CR26","doi-asserted-by":"crossref","unstructured":"Zhang L, Chen Y, Wang H, Xu Z, Wang Y, Li S et al (2021) Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer. J Immunother Cancer 9","DOI":"10.1136\/jitc-2021-002356"},{"key":"3523_CR27","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12885-021-07942-1","volume":"21","author":"J Xiao","year":"2021","unstructured":"Xiao J, Li W, Huang Y, Huang M, Li S, Zhai X et al (2021) A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer. BMC Cancer 21:282","journal-title":"BMC Cancer"},{"key":"3523_CR28","doi-asserted-by":"publisher","first-page":"414","DOI":"10.21037\/hbsn-20-338","volume":"9","author":"J Lin","year":"2020","unstructured":"Lin J, Yang X, Long J, Zhao S, Mao J, Wang D et al (2020) Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobiliary Surg Nutr 9:414\u2013424","journal-title":"Hepatobiliary Surg Nutr"},{"key":"3523_CR29","doi-asserted-by":"crossref","unstructured":"Yang X, Chen B, Wang Y, Wang Y, Long J, Zhang N et al (2023) Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients. Hepatol Int 1\u201311","DOI":"10.1007\/s12072-022-10480-y"},{"key":"3523_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12943-018-0864-3","volume":"17","author":"M Yi","year":"2018","unstructured":"Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X et al (2018) Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors. Mol Cancer 17:129","journal-title":"Mol Cancer"},{"key":"3523_CR31","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41416-022-01932-1","volume":"127","author":"A Tomczak","year":"2022","unstructured":"Tomczak A, Springfeld C, Dill MT, Chang DH, Kazdal D, Wagner U et al (2022) Precision oncology for intrahepatic cholangiocarcinoma in clinical practice. Br J Cancer 127:1701\u20131708","journal-title":"Br J Cancer"},{"key":"3523_CR32","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/hep.31829","volume":"74","author":"T Boerner","year":"2021","unstructured":"Boerner T, Drill E, Pak LM, Nguyen B, Sigel CS, Doussot A et al (2021) Genetic determinants of outcome in intrahepatic cholangiocarcinoma. Hepatology 74:1429\u20131444","journal-title":"Hepatology"},{"key":"3523_CR33","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1158\/2159-8290.CD-21-1077","volume":"12","author":"MJ Wu","year":"2022","unstructured":"Wu MJ, Shi L, Dubrot J, Merritt J, Vijay V, Wei TY et al (2022) Mutant IDH inhibits IFN\u03b3-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma. Cancer Discov 12:812\u2013835","journal-title":"Cancer Discov"},{"key":"3523_CR34","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41419-018-1087-7","volume":"9","author":"XX Chen","year":"2018","unstructured":"Chen XX, Yin Y, Cheng JW, Huang A, Hu B, Zhang X et al (2018) BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1\/2 and JNK\/c-Jun pathways. Cell Death Dis 9:1036","journal-title":"Cell Death Dis"},{"key":"3523_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2019.06.003","volume":"78","author":"A Mahipal","year":"2019","unstructured":"Mahipal A, Tella SH, Kommalapati A, Anaya D, Kim R (2019) FGFR2 genomic aberrations: achilles heel in the management of advanced cholangiocarcinoma. Cancer Treat Rev 78:1\u20137","journal-title":"Cancer Treat Rev"},{"key":"3523_CR36","doi-asserted-by":"publisher","first-page":"253","DOI":"10.21037\/hbsn-20-475","volume":"11","author":"N Munugala","year":"2022","unstructured":"Munugala N, Maithel SK, Shroff RT (2022) Novel biomarkers and the future of targeted therapies in cholangiocarcinoma: a narrative review. Hepatobiliary Surg Nutr 11:253\u2013266","journal-title":"Hepatobiliary Surg Nutr"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03523-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-023-03523-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03523-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T03:05:41Z","timestamp":1697252741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-023-03523-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,3]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["3523"],"URL":"https:\/\/doi.org\/10.1007\/s00262-023-03523-2","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,3]]},"assertion":[{"value":"30 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Ethics Committee of Peking Union Medical College Hospital (No. JS-1391), and was conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}